Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
143.95
-3.41 (-2.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
June 23, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...
Via
Benzinga
Exposures
Product Safety
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
June 07, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
June 01, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
May 26, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces New Advances in ATTR Amyloidosis Program
May 11, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
May 04, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
May 03, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript
April 29, 2021
ALNY earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
April 29, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
April 19, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
April 17, 2021
The FDA and CDC announced their recommendation to pause the use of Johnson & Johnson's JNJ COVID-19 vaccine following incidences of severe clots. J&J's pain turned into gains for other COVID-19 vaccine...
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
April 17, 2021
Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American...
Via
Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
April 15, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
April 11, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
April 08, 2021
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.